Massachusetts company Intellia Therapeutics and Massachusetts 's Intellia Therapeutics are arbitrating to resolve a complex CRISPR licensing dispute. CARIBOU In a filing from 2014 , Intellia alleged Intellia violated a 2014 agreement by attempting to license two patent families, developed using Caribou Biosciences 's exclusive research into human therapeutics, to unnamed third parties. Caribou CEO Rachel Haurwitz said the licence was "specific to one CRISPR technology" and not others.
Massachusetts company Intellia Therapeutics and Massachusetts 's Intellia Therapeutics are arbitrating to resolve a complex CRISPR licensing dispute. In a filing from 2014 , Intellia alleged Intellia violated a 2014 agreement by attempting to license two patent families, developed using Caribou Biosciences 's exclusive research into human therapeutics, to unnamed third parties. Caribou CEO Rachel Haurwitz said the licence was "specific to one CRISPR technology" and not others.